JP2021529766A5 - - Google Patents
Info
- Publication number
- JP2021529766A5 JP2021529766A5 JP2020573242A JP2020573242A JP2021529766A5 JP 2021529766 A5 JP2021529766 A5 JP 2021529766A5 JP 2020573242 A JP2020573242 A JP 2020573242A JP 2020573242 A JP2020573242 A JP 2020573242A JP 2021529766 A5 JP2021529766 A5 JP 2021529766A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- seq
- subject
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693218P | 2018-07-02 | 2018-07-02 | |
| US62/693,218 | 2018-07-02 | ||
| US201862697353P | 2018-07-12 | 2018-07-12 | |
| US62/697,353 | 2018-07-12 | ||
| PCT/US2019/040196 WO2020010024A1 (en) | 2018-07-02 | 2019-07-01 | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529766A JP2021529766A (ja) | 2021-11-04 |
| JPWO2020010024A5 JPWO2020010024A5 (https=) | 2022-07-11 |
| JP2021529766A5 true JP2021529766A5 (https=) | 2022-07-11 |
| JP7513533B2 JP7513533B2 (ja) | 2024-07-09 |
Family
ID=69060543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573242A Active JP7513533B2 (ja) | 2018-07-02 | 2019-07-01 | リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210155682A1 (https=) |
| EP (1) | EP3817768A4 (https=) |
| JP (1) | JP7513533B2 (https=) |
| KR (1) | KR20210056325A (https=) |
| CN (1) | CN112839672A (https=) |
| CA (1) | CA3105071A1 (https=) |
| WO (1) | WO2020010024A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| CA3172880A1 (en) * | 2020-04-27 | 2021-11-04 | Sotirios Tsimikas | Isoform-independent antibodies to lipoprotein(a) |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727102B1 (en) * | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| UA100255C2 (uk) * | 2007-12-28 | 2012-12-10 | Біоінвент Інтернешенл Аб | Фармацевтична композиція |
| AR076640A1 (es) * | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
| ES2992345T3 (es) * | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2019
- 2019-07-01 JP JP2020573242A patent/JP7513533B2/ja active Active
- 2019-07-01 CN CN201980057029.4A patent/CN112839672A/zh active Pending
- 2019-07-01 EP EP19830488.3A patent/EP3817768A4/en active Pending
- 2019-07-01 WO PCT/US2019/040196 patent/WO2020010024A1/en not_active Ceased
- 2019-07-01 US US17/257,055 patent/US20210155682A1/en active Pending
- 2019-07-01 CA CA3105071A patent/CA3105071A1/en active Pending
- 2019-07-01 KR KR1020217003215A patent/KR20210056325A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002171A5 (https=) | ||
| JP2017160208A5 (https=) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2020500152A5 (https=) | ||
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| JP2013543501A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2021529766A5 (https=) | ||
| JP2021532126A5 (https=) | ||
| JP2020535149A5 (https=) | ||
| JP2020502261A5 (https=) | ||
| JP2021530438A5 (https=) | ||
| JP2021511024A5 (https=) | ||
| JP2021523138A5 (https=) | ||
| JPWO2020010024A5 (https=) | ||
| JPWO2020023530A5 (https=) | ||
| CA3185105A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| TW202120546A (zh) | 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法 | |
| JPWO2019140216A5 (https=) | ||
| IL292493A (en) | Stable aqueous anti-tfpi antibody formulation | |
| JPWO2023079485A5 (https=) | ||
| RU2832323C1 (ru) | Способ лечения с использованием антитела против CCL24 | |
| JPWO2019232070A5 (https=) | ||
| JPWO2019215701A5 (https=) | ||
| US20230235037A1 (en) | Method of treatment using anti-ccl24 antibody |